Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Correction to: Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement.

Goldman JL, Chung WH, Lee BR, Chen CB, Lu CW, Hoetzenecker W, Micheletti R, Yasuda SU, Margolis DJ, Shear NH, Struewing JP, Pirmohamed M.

Eur J Clin Pharmacol. 2019 Jun 29. doi: 10.1007/s00228-019-02710-4. [Epub ahead of print]

PMID:
31254013
2.

Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement.

Goldman JL, Chung WH, Lee BR, Chen CB, Lu CW, Hoetzenecker W, Micheletti R, Yasuda SU, Margolis DJ, Shear NH, Struewing JP, Pirmohamed M.

Eur J Clin Pharmacol. 2019 Aug;75(8):1135-1141. doi: 10.1007/s00228-019-02670-9. Epub 2019 Mar 27. Erratum in: Eur J Clin Pharmacol. 2019 Jun 29;:.

PMID:
30918988
3.

SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.

White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, Chodosh J, Cibotti R, Davis R, Denny JC, Dodiuk-Gad RP, Ergen EN, Goldman JL, Holmes JH 4th, Hung SI, Lacouture ME, Lehloenya RJ, Mallal S, Manolio TA, Micheletti RG, Mitchell CM, Mockenhaupt M, Ostrov DA, Pavlos R, Pirmohamed M, Pope E, Redwood A, Rosenbach M, Rosenblum MD, Roujeau JC, Saavedra AP, Saeed HN, Struewing JP, Sueki H, Sukasem C, Sung C, Trubiano JA, Weintraub J, Wheatley LM, Williams KB, Worley B, Chung WH, Shear NH, Phillips EJ.

J Allergy Clin Immunol Pract. 2018 Jan - Feb;6(1):38-69. doi: 10.1016/j.jaip.2017.11.023. Review.

4.

Meeting research needs with postmortem biospecimen donation: summary of recommendations for postmortem recovery of normal human biospecimens for research.

Mucci NR, Moore HM, Brigham LE, Goldthwaite CA, Little AR, Lockhart NC, Scott MP, Struewing JP, Vincent SL, Compton CC; cancer Human Biobank (caHUB) Acquisition of Normal Tissue Subgroup, National Cancer Institute.

Biopreserv Biobank. 2013 Apr;11(2):77-82. doi: 10.1089/bio.2012.0063. Erratum in: Biopreserv Biobank. 2013 Jun;11(3):191.

PMID:
24845428
5.

The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies.

McCarty CA, Chisholm RL, Chute CG, Kullo IJ, Jarvik GP, Larson EB, Li R, Masys DR, Ritchie MD, Roden DM, Struewing JP, Wolf WA; eMERGE Team.

BMC Med Genomics. 2011 Jan 26;4:13. doi: 10.1186/1755-8794-4-13.

6.

No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families.

Korde LA, Mueller CM, Loud JT, Struewing JP, Nichols K, Greene MH, Mai PL.

Breast Cancer Res Treat. 2011 Jan;125(1):169-73. doi: 10.1007/s10549-010-0923-y. Epub 2010 May 11.

7.

Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma.

Mai PL, Chatterjee N, Hartge P, Tucker M, Brody L, Struewing JP, Wacholder S.

PLoS One. 2009;4(3):e4812. doi: 10.1371/journal.pone.0004812. Epub 2009 Mar 11.

8.

FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation.

Udler MS, Meyer KB, Pooley KA, Karlins E, Struewing JP, Zhang J, Doody DR, MacArthur S, Tyrer J, Pharoah PD, Luben R, Bernstein L, Kolonel LN, Henderson BE, Le Marchand L, Ursin G, Press MF, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Kang D, Yoo KY, Noh DY, Ahn SH, Ponder BA, Haiman CA, Malone KE, Dunning AM, Ostrander EA, Easton DF; SEARCH Collaborators.

Hum Mol Genet. 2009 May 1;18(9):1692-703. doi: 10.1093/hmg/ddp078. Epub 2009 Feb 17.

9.

Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among US radiologic technologists.

Sigurdson AJ, Bhatti P, Chang SC, Rajaraman P, Doody MM, Bowen L, Simon SL, Weinstock RM, Linet MS, Rosenstein M, Stovall M, Alexander BH, Preston DL, Struewing JP.

Breast Cancer Res Treat. 2009 Nov;118(1):177-84. doi: 10.1007/s10549-009-0307-3. Epub 2009 Feb 12.

10.

Thyroid nodules, polymorphic variants in DNA repair and RET-related genes, and interaction with ionizing radiation exposure from nuclear tests in Kazakhstan.

Sigurdson AJ, Land CE, Bhatti P, Pineda M, Brenner A, Carr Z, Gusev BI, Zhumadilov Z, Simon SL, Bouville A, Rutter JL, Ron E, Struewing JP.

Radiat Res. 2009 Jan;171(1):77-88. doi: 10.1667/RR1327.1.

11.

Breast cancer risk polymorphisms and interaction with ionizing radiation among U.S. radiologic technologists.

Bhatti P, Doody MM, Alexander BH, Yuenger J, Simon SL, Weinstock RM, Rosenstein M, Stovall M, Abend M, Preston DL, Pharoah P, Struewing JP, Sigurdson AJ.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2007-11. doi: 10.1158/1055-9965.EPI-08-0300.

12.

Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics.

Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G, González-Neira A, Benítez J, Zamora P, Brauch H, Justenhoven C, Hamann U, Ko YD, Bruening T, Haas S, Dörk T, Schürmann P, Hillemanns P, Bogdanova N, Bremer M, Karstens JH, Fagerholm R, Aaltonen K, Aittomäki K, von Smitten K, Blomqvist C, Mannermaa A, Uusitupa M, Eskelinen M, Tengström M, Kosma VM, Kataja V, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X; Australian Ovarian Cancer Management Group; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Devilee P, van Asperen CJ, Jacobi CE, Tollenaar RA, Huijts PE, Klijn JG, Chang-Claude J, Kropp S, Slanger T, Flesch-Janys D, Mutschelknauss E, Salazar R, Wang-Gohrke S, Couch F, Goode EL, Olson JE, Vachon C, Fredericksen ZS, Giles GG, Baglietto L, Severi G, Hopper JL, English DR, Southey MC, Haiman CA, Henderson BE, Kolonel LN, Le Marchand L, Stram DO, Hunter DJ, Hankinson SE, Cox DG, Tamimi R, Kraft P, Sherman ME, Chanock SJ, Lissowska J, Brinton LA, Peplonska B, Klijn JG, Hooning MJ, Meijers-Heijboer H, Collee JM, van den Ouweland A, Uitterlinden AG, Liu J, Lin LY, Yuqing L, Humphreys K, Czene K, Cox A, Balasubramanian SP, Cross SS, Reed MW, Blows F, Driver K, Dunning A, Tyrer J, Ponder BA, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gabrieau V, Sigurdson A, Doody M, Struewing JP, Alexander B, Easton DF, Pharoah PD.

PLoS Genet. 2008 Apr 25;4(4):e1000054. doi: 10.1371/journal.pgen.1000054.

13.

Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping.

Olshen AB, Gold B, Lohmueller KE, Struewing JP, Satagopan J, Stefanov SA, Eskin E, Kirchhoff T, Lautenberger JA, Klein RJ, Friedman E, Norton L, Ellis NA, Viale A, Lee CS, Borgen PI, Clark AG, Offit K, Boyd J.

BMC Genet. 2008 Feb 5;9:14. doi: 10.1186/1471-2156-9-14.

14.

Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.

Chodick G, Struewing JP, Ron E, Rutter JL, Iscovich J.

Eur J Med Genet. 2008 Mar-Apr;51(2):141-7. Epub 2007 Nov 22.

15.

RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.

Antoniou AC, Sinilnikova OM, Simard J, Léoné M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ; Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers Study (GEMO), Rebbeck TR, Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J, Narod SA, Tomlinson G, Olopade OI, Godwin A, Isaacs C, Jakubowska A, Lubinski J, Gronwald J, Górski B, Byrski T, Huzarski T, Peock S, Cook M, Baynes C, Murray A, Rogers M, Daly PA, Dorkins H; Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE), Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Niederacher D, Deissler H; German Consortium for Hereditary Breast and Ovarian Cancer (GCHBOC), Spurdle AB, Chen X, Waddell N, Cloonan N; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab), Kirchhoff T, Offit K, Friedman E, Kaufmann B, Laitman Y, Galore G, Rennert G, Lejbkowicz F, Raskin L, Andrulis IL, Ilyushik E, Ozcelik H, Devilee P, Vreeswijk MP, Greene MH, Prindiville SA, Osorio A, Benitez J, Zikan M, Szabo CI, Kilpivaara O, Nevanlinna H, Hamann U, Durocher F, Arason A, Couch FJ, Easton DF, Chenevix-Trench G; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

Am J Hum Genet. 2007 Dec;81(6):1186-200. Epub 2007 Oct 16.

16.

Polymorphisms in apoptosis- and proliferation-related genes, ionizing radiation exposure, and risk of breast cancer among U.S. Radiologic Technologists.

Sigurdson AJ, Bhatti P, Doody MM, Hauptmann M, Bowen L, Simon SL, Weinstock RM, Linet MS, Rosenstein M, Stovall M, Alexander BH, Preston DL, Struewing JP, Rajaraman P.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2000-7.

17.
18.

Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. Radiologic technologists.

Bhatti P, Struewing JP, Alexander BH, Hauptmann M, Bowen L, Mateus-Pereira LH, Pineda MA, Simon SL, Weinstock RM, Rosenstein M, Stovall M, Preston DL, Linet MS, Doody MM, Sigurdson AJ.

Int J Cancer. 2008 Jan 1;122(1):177-82.

19.

AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study.

Couch FJ, Sinilnikova O, Vierkant RA, Pankratz VS, Fredericksen ZS, Stoppa-Lyonnet D, Coupier I, Hughes D, Hardouin A, Berthet P, Peock S, Cook M, Baynes C, Hodgson S, Morrison PJ, Porteous ME, Jakubowska A, Lubinski J, Gronwald J, Spurdle AB; kConFab, Schmutzler R, Versmold B, Engel C, Meindl A, Sutter C, Horst J, Schaefer D, Offit K, Kirchhoff T, Andrulis IL, Ilyushik E, Glendon G, Devilee P, Vreeswijk MP, Vasen HF, Borg A, Backenhorn K, Struewing JP, Greene MH, Neuhausen SL, Rebbeck TR, Nathanson K, Domchek S, Wagner T, Garber JE, Szabo C, Zikan M, Foretova L, Olson JE, Sellers TA, Lindor N, Nevanlinna H, Tommiska J, Aittomaki K, Hamann U, Rashid MU, Torres D, Simard J, Durocher F, Guenard F, Lynch HT, Isaacs C, Weitzel J, Olopade OI, Narod S, Daly MB, Godwin AK, Tomlinson G, Easton DF, Chenevix-Trench G, Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2.

Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1416-21.

20.

Genome-wide association study identifies novel breast cancer susceptibility loci.

Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R; SEARCH collaborators, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J, Fletcher O, Johnson N, Seal S, Stratton MR, Rahman N, Chenevix-Trench G, Bojesen SE, Nordestgaard BG, Axelsson CK, Garcia-Closas M, Brinton L, Chanock S, Lissowska J, Peplonska B, Nevanlinna H, Fagerholm R, Eerola H, Kang D, Yoo KY, Noh DY, Ahn SH, Hunter DJ, Hankinson SE, Cox DG, Hall P, Wedren S, Liu J, Low YL, Bogdanova N, Schürmann P, Dörk T, Tollenaar RA, Jacobi CE, Devilee P, Klijn JG, Sigurdson AJ, Doody MM, Alexander BH, Zhang J, Cox A, Brock IW, MacPherson G, Reed MW, Couch FJ, Goode EL, Olson JE, Meijers-Heijboer H, van den Ouweland A, Uitterlinden A, Rivadeneira F, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Hopper JL, McCredie M, Southey M, Giles GG, Schroen C, Justenhoven C, Brauch H, Hamann U, Ko YD, Spurdle AB, Beesley J, Chen X; kConFab; AOCS Management Group, Mannermaa A, Kosma VM, Kataja V, Hartikainen J, Day NE, Cox DR, Ponder BA.

Nature. 2007 Jun 28;447(7148):1087-93.

21.

Systematic analysis of genetic alterations in tumors using Cancer Genome WorkBench (CGWB).

Zhang J, Finney RP, Rowe W, Edmonson M, Yang SH, Dracheva T, Jen J, Struewing JP, Buetow KH.

Genome Res. 2007 Jul;17(7):1111-7. Epub 2007 May 24.

22.

A common coding variant in CASP8 is associated with breast cancer risk.

Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, Scollen S, Baynes C, Ponder BA, Chanock S, Lissowska J, Brinton L, Peplonska B, Southey MC, Hopper JL, McCredie MR, Giles GG, Fletcher O, Johnson N, dos Santos Silva I, Gibson L, Bojesen SE, Nordestgaard BG, Axelsson CK, Torres D, Hamann U, Justenhoven C, Brauch H, Chang-Claude J, Kropp S, Risch A, Wang-Gohrke S, Schürmann P, Bogdanova N, Dörk T, Fagerholm R, Aaltonen K, Blomqvist C, Nevanlinna H, Seal S, Renwick A, Stratton MR, Rahman N, Sangrajrang S, Hughes D, Odefrey F, Brennan P, Spurdle AB, Chenevix-Trench G; Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer, Beesley J, Mannermaa A, Hartikainen J, Kataja V, Kosma VM, Couch FJ, Olson JE, Goode EL, Broeks A, Schmidt MK, Hogervorst FB, Van't Veer LJ, Kang D, Yoo KY, Noh DY, Ahn SH, Wedrén S, Hall P, Low YL, Liu J, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Sigurdson AJ, Stredrick DL, Alexander BH, Struewing JP, Pharoah PD, Easton DF; Breast Cancer Association Consortium.

Nat Genet. 2007 Mar;39(3):352-8. Epub 2007 Feb 11. Erratum in: Nat Genet. 2007 May;39(5):688.

PMID:
17293864
23.

Papillary thyroid cancer and polymorphic variants in TSHR- and RET-related genes: a nested case-control study within a cohort of U.S. radiologic technologists.

Lönn S, Bhatti P, Alexander BH, Pineda MA, Doody MM, Struewing JP, Sigurdson AJ.

Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):174-7.

24.

BRCA1/2 testing in hereditary breast and ovarian cancer families III: risk perception and screening.

McInerney-Leo A, Hadley D, Kase RG, Giambarresi TR, Struewing JP, Biesecker BB.

Am J Med Genet A. 2006 Oct 15;140(20):2198-206.

PMID:
16969872
25.

Candidate single nucleotide polymorphism selection using publicly available tools: a guide for epidemiologists.

Bhatti P, Church DM, Rutter JL, Struewing JP, Sigurdson AJ.

Am J Epidemiol. 2006 Oct 15;164(8):794-804. Epub 2006 Aug 21.

PMID:
16923772
26.

The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer.

Stredrick DL, Garcia-Closas M, Pineda MA, Bhatti P, Alexander BH, Doody MM, Lissowska J, Peplonska B, Brinton LA, Chanock SJ, Struewing JP, Sigurdson AJ.

Hum Mutat. 2006 Jun;27(6):538-44.

27.

Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses.

García-Closas M, Egan KM, Newcomb PA, Brinton LA, Titus-Ernstoff L, Chanock S, Welch R, Lissowska J, Peplonska B, Szeszenia-Dabrowska N, Zatonski W, Bardin-Mikolajczak A, Struewing JP.

Hum Genet. 2006 May;119(4):376-88. Epub 2006 Feb 17.

PMID:
16485136
28.

The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Spurdle AB, Antoniou AC, Kelemen L, Holland H, Peock S, Cook MR, Smith PL, Greene MH, Simard J, Plourde M, Southey MC, Godwin AK, Beck J, Miron A, Daly MB, Santella RM, Hopper JL, John EM, Andrulis IL, Durocher F, Struewing JP, Easton DF, Chenevix-Trench G; Australian Breast Cancer Family Study; Australian Jewish Breast Cancer Study; Breast Cancer Family Registry; Interdisciplinary Health Research International Team on Breast Cancer Susceptibility; Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer; Epidemiological Study of Familial Breast Cancer Study Collaborators.

Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):76-9.

29.

Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.

Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH.

J Clin Oncol. 2005 Dec 1;23(34):8629-35.

PMID:
16314625
30.

Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping.

Ellis NA, Kirchhoff T, Mitra N, Ye TZ, Chuai S, Huang H, Nafa K, Norton L, Neuhausen S, Gordon D, Struewing JP, Narod S, Offit K.

Genet Epidemiol. 2006 Jan;30(1):48-61.

PMID:
16206141
31.

DNA damage among thyroid cancer and multiple cancer cases, controls, and long-lived individuals.

Sigurdson AJ, Hauptmann M, Alexander BH, Doody MM, Thomas CB, Struewing JP, Jones IM.

Mutat Res. 2005 Oct 3;586(2):173-88.

PMID:
16099702
32.

Skewed X chromosome inactivation and early-onset breast cancer.

Struewing JP, Pineda MA, Sherman ME, Lissowska J, Brinton LA, Peplonska B, Bardin-Mikolajczak A, Garcia-Closas M.

J Med Genet. 2006 Jan;43(1):48-53. Epub 2005 May 27.

33.
34.

BRCA1 in special populations.

Struewing JP.

Breast Dis. 1998 Apr;10(1-2):71-5.

PMID:
15687550
35.

BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.

McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, Lerman C, Struewing JP.

Am J Med Genet A. 2005 Mar 1;133A(2):165-9.

PMID:
15633195
36.

Breast cancer risks for BRCA1/2 carriers.

Wacholder S, Struewing JP, Hartge P, Greene MH, Tucker MA.

Science. 2004 Dec 24;306(5705):2187-91; author reply 2187-91. No abstract available.

PMID:
15622558
37.

Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study.

Rutter JL, Bromley CM, Goldstein AM, Elder DE, Holly EA, Guerry D 4th, Hartge P, Struewing JP, Hogg D, Halpern A, Sagebiel RW, Tucker MA.

Cancer. 2004 Dec 15;101(12):2809-16.

38.

CHEK2:1100delC and female breast cancer in the United States.

Mateus Pereira LH, Sigurdson AJ, Doody MM, Pineda MA, Alexander BH, Greene MH, Struewing JP.

Int J Cancer. 2004 Nov 10;112(3):541-3. No abstract available.

39.

BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.

McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, Lerman C, Struewing JP.

Am J Med Genet A. 2004 Oct 15;130A(3):221-7.

PMID:
15378542
40.

Prospective risk of cancer in CDKN2A germline mutation carriers.

Goldstein AM, Struewing JP, Fraser MC, Smith MW, Tucker MA.

J Med Genet. 2004 Jun;41(6):421-4.

41.

BRCA1 and sex ratio.

Struewing JP, Hartge P, Wacholder S, Tucker MA, Greene MH.

Eur J Hum Genet. 2004 Aug;12(8):663-7.

42.

Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.

Sigurdson AJ, Hauptmann M, Chatterjee N, Alexander BH, Doody MM, Rutter JL, Struewing JP.

BMC Cancer. 2004 Mar 12;4:9.

43.

XPD gene polymorphism and host characteristics in the association with cutaneous malignant melanoma risk.

Baccarelli A, Calista D, Minghetti P, Marinelli B, Albetti B, Tseng T, Hedayati M, Grossman L, Landi G, Struewing JP, Landi MT.

Br J Cancer. 2004 Jan 26;90(2):497-502.

44.

Performance of high-throughput DNA quantification methods.

Haque KA, Pfeiffer RM, Beerman MB, Struewing JP, Chanock SJ, Bergen AW.

BMC Biotechnol. 2003 Oct 28;3:20.

45.

Segregation analysis of 231 Ashkenazi Jewish families for evidence of additional breast cancer susceptibility genes.

Kaufman DJ, Beaty TH, Struewing JP.

Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1045-52.

46.

A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology.

Giusti RM, Rutter JL, Duray PH, Freedman LS, Konichezky M, Fisher-Fischbein J, Greene MH, Maslansky B, Fischbein A, Gruber SB, Rennert G, Ronchetti RD, Hewitt SM, Struewing JP, Iscovich J.

J Med Genet. 2003 Oct;40(10):787-92. No abstract available. Erratum in: J Med Genet. 2004 Jan;41(1):51.

47.

Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.

Hauptmann M, Sigurdson AJ, Chatterjee N, Rutter JL, Hill DA, Doody MM, Struewing JP.

J Natl Cancer Inst. 2003 Aug 20;95(16):1251-2. No abstract available.

PMID:
12928354
48.

Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.

Rutter JL, Smith AM, Dávila MR, Sigurdson AJ, Giusti RM, Pineda MA, Doody MM, Tucker MA, Greene MH, Zhang J, Struewing JP.

Hum Mutat. 2003 Aug;22(2):121-8.

PMID:
12872252
49.

Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.

Rutter JL, Wacholder S, Chetrit A, Lubin F, Menczer J, Ebbers S, Tucker MA, Struewing JP, Hartge P.

J Natl Cancer Inst. 2003 Jul 16;95(14):1072-8.

PMID:
12865453
50.

CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.

Rutter JL, Goldstein AM, Dávila MR, Tucker MA, Struewing JP.

Oncogene. 2003 Jul 10;22(28):4444-8.

PMID:
12853981

Supplemental Content

Loading ...
Support Center